

**bs-2808R****[ Primary Antibody ]**
**Bioss**  
**ANTIBODIES**

www.bioss.com.cn

sales@bioss.com.cn

techsupport@bioss.com.cn

400-901-9800

## Jak3 Rabbit pAb

### DATASHEET

**Host:** Rabbit**Isotype:** IgG**Clonality:** Polyclonal**GeneID:** 3718**SWISS:** P52333**Target:** Jak3**Immunogen:** KLH conjugated synthetic peptide derived from human Jak3: 601-700/1124.**Purification:** affinity purified by Protein A**Concentration:** 1mg/ml

**Storage:** 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.  
 Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

**Background:** The protein encoded by this gene is a member of the Janus kinase (JAK) family of tyrosine kinases involved in cytokine receptor-mediated intracellular signal transduction. It is predominantly expressed in immune cells and transduces a signal in response to its activation via tyrosine phosphorylation by interleukin receptors. Mutations in this gene are associated with autosomal SCID (severe combined immunodeficiency disease). [provided by RefSeq, Jul 2008]


**Applications:** WB (1:500-2000)**IHC-P** (1:100-500)**IHC-F** (1:100-500)**IF** (1:100-500)**Flow-Cyt** (1ug/test)

**Reactivity:** Human, Mouse, Rat  
 (predicted: Pig, Cow, Dog, Horse)


**Predicted MW.:** 125 kDa

**Subcellular Location:** Cytoplasm


### VALIDATION IMAGES




Sample: SP2/0 Cell (Mouse) Lysate at 40 ug  
 Jurkat Cell (Human) Lysate at 40 ug K562 Cell (Human) Lysate at 40 ug  
 Primary: Anti- Jak3 (bs-2808R) at 1/300 dilution  
 Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution  
 Predicted band size: 125 kD  
 Observed band size: 125 kD




Sample: Lane 1: Mouse Thymus tissue lysates  
 Lane 2: Rat Lymph node tissue lysates  
 Lane 3: Human Jurkat cell lysates  
 Lane 4: Human Hela cell lysates  
 Lane 5: Human Molt-4 cell lysates  
 Primary: Anti-Jak3 (bs-2808R) at 1/1000 dilution  
 Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution  
 Predicted band size: 125 kDa  
 Observed band size: 115 kDa



Tissue/cell: human lung carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer (0.01M, pH 6.0), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Incubation: Anti-Jak3 Polyclonal Antibody, Unconjugated(bs-2808R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining



Blank control (black line) :Molt4. Primary Antibody (green line): Rabbit Anti-Jak3 antibody (bs-2808R) Dilution:1ug/Test; Secondary Antibody (white blue line) : Goat anti-rabbit IgG-AF488 Dilution: 0.5ug/Test. Isotype control (orange line) : Normal Rabbit IgG Protocol The



Blank control:Molt-4. Primary Antibody (green line): Rabbit Anti-Jak3 antibody (bs-2808R) Dilution: 0.2ug /10<sup>6</sup> cells; Isotype Control Antibody (orange line): Rabbit IgG . Secondary Antibody : Goat anti-rabbit IgG-PE Dilution: 0.2ug /test. Protocol The cells were fixed with 4% PFA

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 90% ice-cold methanol for 20 min at -20°C, The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.

(10min at room temperature)and then permeabilized with 20% PBST for 20 min at -20°C. The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.

---

## — SELECTED CITATIONS —

- **[IF=17.4]** Hui Yan. et al. Elaboration a ROS-responsive darutigenol prodrug nanoassemblies for inflammatory arthritis treatment. NANO TODAY. 2024 Apr;55:102220 WB ;Mouse. 10.1016/j.nantod.2024.102220
- **[IF=6.291]** Changjiang Liu. et al. Cypermethrin triggers YY1-mediated testosterone biosynthesis suppression. Ecotox Environ Safe. 2021 Dec;225:112792 WB ;Rat. 10.1016/j.ecoenv.2021.112792
- **[IF=5.195]** Yong Wang. et al. An integrated network pharmacology approach reveals that Darutigenol reduces inflammation and cartilage degradation in a mouse collagen-induced arthritis model by inhibiting the JAK-STAT3 pathway. J ETHNOPHARMACOL. 2023 May;;116574 WB ;Mouse. 37160212
- **[IF=5.4]** Ting Xiao. et al. Ameliorative effect of Alangium chinense (Lour.) Harms on rheumatoid arthritis by reducing autophagy with targeting regulate JAK3-STAT3 and COX-2 pathways. J ETHNOPHARMACOL. 2023 Sep;;117133 IHC,WB ;Rat. 37690476
- **[IF=4.46]** Xing Chang. et al. 1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42) inhibits cell proliferation and induces apoptosis via inhibiting ALK and its downstream pathways in Karpas299 cells. TOXICOL APPL PHARM. 2022 Sep;450:116156 WB ;Human. 35803438